Current preclinical studies of MCL-1 inhibition or downregulation of MCL-1 via inhibiting B-cell lymphoma 2 (Bcl-2) in FLT3-ITD-mutated AML are promising. Here, FLT3 is linked to acute myeloid leukemia.